about
Prolonged dual antiplatelet therapy in renal failure: a challenging trade-offRepositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis.Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group.Long-term safety of drug-eluting stents.Interventional treatment for structural heart disease: who is deciding, and can we afford it?Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry.Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials).Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.Incidence and Predictors of Cardiomyocyte Injury in Elective Coronary Angiography.First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot StudyStent thrombosis after coronary stent implantation: a protective effect of high-dose statin therapy?By a Hair's Breadth.Predicting Mortality After Transcatheter Aortic Valve Replacement: External Validation of the Transcatheter Valve Therapy Registry Model.Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials.Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus.Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-study.Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy.Prognostic value of "routine" cardiac stress imaging 5 years after percutaneous coronary intervention: the prospective long-term observational BASKET (Basel Stent Kosteneffektivitäts Trial) LATE IMAGING study.New-onset or Pre-existing Atrial Fibrillation in Acute Coronary Syndromes: Two Distinct Phenomena With a Similar Prognosis.Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.First-in-man Portico® transcatheter aortic valve-in-valve implantation in a degenerated 19 mm Mitroflow® aortic pericardial heart valve.The Neurocardiogenic Spectrum in Subarachnoid Hemorrhage: A Case Report and Review of the Literature.Supra-annular sizing for transcatheter valve implantation in bicuspid aortic stenosis.Temporal Trends in Adoption and Outcomes of Transcatheter Aortic Valve Implantation: A Swisstavi Registry AnalysisClinical utility of circulating interleukin-6 concentrations in the detection of functionally relevant coronary artery diseaseCompeting risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE IITwenty-Year Trends in the Incidence and Outcome of Cardiogenic Shock in AMIS Plus RegistryDrug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trials.Mens sana in corpore sano revisitedStents in saphenous vein graftsImpact of aetiology of mitral regurgitation on outcome after Mitraclip: lessons learned from MitraSwiss RegistryElectrophysiology Testing to Stratify Patients With Left Bundle Branch Block After Transcatheter Aortic Valve ImplantationVollständig resorbierbare Stents – eine neue Ära in der Behandlung der koronaren Herzkrankheit?Survival After Coronary Revascularization With Paclitaxel-Coated BalloonsSex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock: A Substudy of the CULPRIT-SHOCK TrialLocal Versus General Anesthesia for Transcatheter Aortic Valve Replacement: A SwissTAVI Registry AnalysisA Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney InjuryA review of recommendations for infective endocarditis prevention in patients undergoing transcatheter aortic valve implantationDo ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials
P50
Q36437445-A33A8E7E-D59A-448E-9E66-4F41F7A27B1EQ37556091-A4E3AD21-987B-4190-BF8D-5722D37BA905Q38132036-725E5B67-A76E-479E-B123-240C0C9D0E42Q38153786-F336AAED-0176-4CAE-B939-906FF5F8E2EEQ38268376-0B409CB8-7A96-4A6D-8954-BA7F7E472135Q38734235-A3A3E384-D4C0-441D-B438-C846A9B235CBQ40508617-4296D86C-1959-418C-9BB3-74513D3D64DEQ40766317-3D7E8BF2-BCC0-4503-8AC5-B1E04B2B6867Q40979493-D97D987E-A177-4683-827A-36CAC0C7D970Q42360036-05085BAD-9540-4556-9294-81D311428D74Q44790290-85DF62D3-158F-43E5-B20C-114C11126BE1Q46775339-49027536-20E9-495D-8B10-5BCA4DC28751Q47615527-6C332C1E-3FCC-46A8-8F2B-E3BBF1EDEE4CQ47693553-A9E98429-FCE7-4FBB-9946-93FF81B98D83Q48158581-ACFA91E4-FD89-4912-B5A6-019756415522Q48163286-10F18C8B-31F7-4A7F-AD98-0A5DDE759FCBQ50899648-6C7250E9-D2CD-43D3-9D14-436315D75EA1Q51051973-5C52C2CF-98BD-4B8C-8862-E1D8399C3149Q51139802-1B57A4A4-874E-4444-842E-2F065FAF6582Q52589401-3982642D-A847-4675-828B-ACB70DFB3505Q52807896-30642F5B-FFED-42EE-BA6F-2C53020D228DQ53618883-716A62DF-0380-4B6F-8389-4AEDCBDF0736Q55030328-30D18471-5E70-4492-866B-DBC52CDCCD5FQ55710364-AA647BAB-D960-492F-B44C-C0EF170D1885Q57288556-0DBDD6F5-3BBE-4ADF-A165-DCC297415267Q57815413-B0F2F85E-84CB-42DE-B194-AAB9D0D31622Q61817383-78B36F4E-027F-4C57-9695-EB6B46C1AA52Q64111908-AEE46F22-0F0E-4C4F-B4DA-48B30CBD2CE0Q64901787-33A5901A-CDAD-4DDD-A493-2E206A6F88CFQ87048707-4056A26A-9D19-4C0F-B5B6-FA2BAD5635E0Q88668151-80F6D003-F49A-4564-8D2B-969E133A2F47Q89501156-F69A0729-0135-45C6-9B8F-1E2B315E8990Q89846946-60FC9149-A3AF-499F-8018-A1A15663609DQ89912444-00F8F3F1-14B9-4F95-8B8D-553B3AA373BCQ90080430-08A28031-2046-4C26-AC51-101825A89036Q90163775-0D3B4B85-DACC-4B15-A9DD-DD30A81F919AQ90181261-F5A41138-A9AB-4914-9D0E-4DAF112F6715Q90327136-F06B1684-FEBE-4B9E-BDB7-9BE3A6C088FEQ90617690-BFA05024-44E0-4DC2-9050-2720B30781E5Q90751182-A425E1FD-FC0B-489F-98A3-879DD7952B02
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Raban Jeger
@en
Raban Jeger
@nl
type
label
Raban Jeger
@en
Raban Jeger
@nl
prefLabel
Raban Jeger
@en
Raban Jeger
@nl
P108
P31
P496
0000-0003-1290-5491